Results 191 to 200 of about 29,030 (239)

A natalizumabkezelés újraindítása és hosszú távú biztonságossága, hatékonysága sclerosis multiplexben a STRATA vizsgálatban [PDF]

, 2014
Csépány, Tünde
core  

Two roads diverged in multiple sclerosis: When is switching therapy effective? [PDF]

Neurotherapeutics
Reder AT.
europepmc   +1 more source

Modulation of Paraoxonase 1 Activity and Asymmetric Dimethylarginine by Immunomodulatory Therapies in Multiple Sclerosis. [PDF]

Int J Mol Sci
Racz L, Lorincz H, Seres I, Kardos L, Paragh G, Csepany T.   +5 more
europepmc   +1 more source

Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR). [PDF]

J Neurol
Monschein T, Untersteiner H, Ponleitner M, Krajnc N, Zrzavy T, Bsteh G, Rommer P, Kornek B, Enzinger C, Di Pauli F, Kraus J, Guger M, Leutmezer F, Berger T, Austrian MS Treatment Registry (AMSTR).   +14 more
europepmc   +1 more source

Should natalizumab be used despite JC virus positivity?-Commentary. [PDF]

Mult Scler
Hedström AK.
europepmc   +1 more source

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability. [PDF]

JAMA Netw Open
Shipley J, Beadnall HN, Sanfilippo PG, Yeh WZ, Horakova D, Havrdova EK, Hradilek P, Kalincik T, Roos I, Prat A, Girard M, Rous Z, Pavelek Z, Gerlach OHH, Lechner-Scott J, Alroughani R, Ozakbas S, Peterka M, Buzzard K, Skibina OG, Maimone D, Foschi M, Surcinelli A, Karabudak R, Spitaleri DLA, Lugaresi A, Tomassini V, Gouider R, Mrabet S, Ferrando BR, Hodgkinson S, Štourac P, Guimarães J, John NA, Macdonell RAL, Meca-Lallana JE, Butzkueven H, van der Walt A, Jokubaitis VG, MSBase Investigator Group.   +39 more
europepmc   +1 more source

Annual 12-Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition. [PDF]

Ann Clin Transl Neurol
Berkovich R, Schneider-Hohendorf T, Baetscher E, Riddle EL, Deffner M, Katsnelson E, Ferrant-Orgettas J, Czerkowicz J, Anderson J, Goelz SE, Schwab N.   +10 more
europepmc   +1 more source

A comparison of JC virus assay performance provided with originator and biosimilar natalizumab. [PDF]

Mult Scler
Varley J, Beyrouti R, Nicholas R, Dorsey R, Brownlee W, Paling D, Mathews J, Dobson R.   +7 more
europepmc   +1 more source

T lymphopenia in multiple sclerosis patients treated with ofatumumab: Even with consideration for CD3 ⁺ CD20⁺ cells. [PDF]

Mult Scler J Exp Transl Clin
Tanaka M, Kinoshita M, Tanaka K.
europepmc   +1 more source